NASDAQ:VRNA Verona Pharma PLC American Depositary Share Q2 2025 Earnings Report $106.02 -0.24 (-0.23%) Closing price 04:00 PM EasternExtended Trading$106.03 +0.01 (+0.01%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Verona Pharma PLC American Depositary Share EPS ResultsActual EPS$0.13Consensus EPS -$0.01Beat/MissBeat by +$0.14One Year Ago EPSN/AVerona Pharma PLC American Depositary Share Revenue ResultsActual Revenue$103.14 millionExpected Revenue$90.41 millionBeat/MissBeat by +$12.73 millionYoY Revenue GrowthN/AVerona Pharma PLC American Depositary Share Announcement DetailsQuarterQ2 2025Date8/6/2025TimeBefore Market OpensConference Call DateWednesday, August 6, 2025Conference Call Time7:00AM ETUpcoming EarningsVerona Pharma PLC American Depositary Share's Q3 2025 earnings is scheduled for Monday, November 3, 2025, with a conference call scheduled at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Verona Pharma PLC American Depositary Share Earnings HeadlinesVerona Pharma (VRNA) Rebounded from Challenging Q1September 16 at 9:55 PM | msn.comVerona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025September 16 at 6:00 AM | globenewswire.comAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."September 19 at 2:00 AM | Brownstone Research (Ad)Here’s What Boosted Verona Pharma plc (VRNA) Share Price by 49%September 12, 2025 | insidermonkey.comHere’s How Wall Street is Reacting to Verona Pharma (VRNA)’s AcquisitionAugust 28, 2025 | finance.yahoo.comMerck’s $10B Verona Deal: A High-Stakes Play in Respiratory CareJuly 29, 2025 | msn.comSee More Verona Pharma PLC American Depositary Share Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Verona Pharma PLC American Depositary Share? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verona Pharma PLC American Depositary Share and other key companies, straight to your email. Email Address About Verona Pharma PLC American Depositary ShareVerona Pharma PLC, trading as American Depositary Shares on NASDAQ under the ticker VRNA, is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for the treatment of respiratory diseases. The company’s primary focus is on creating first-in-class and best-in-class medicines to improve lung function and quality of life in patients suffering from chronic obstructive pulmonary disease (COPD), cystic fibrosis and other airway conditions. The company’s lead product candidate, ensifentrine, is a dual phosphodiesterase 3 and 4 inhibitor with bronchodilator and anti-inflammatory properties. Ensifentrine has completed multiple Phase 2 and Phase 3 clinical trials assessing its efficacy and safety as an inhaled therapy, both as a monotherapy and as an add-on to existing standard of care. Verona Pharma continues to work toward regulatory submissions and potential commercialization partnerships in key markets. Headquartered in London, Verona Pharma operates research and development facilities in both the United Kingdom and the United States. The company leverages collaborations with contract research organizations, clinical trial sites and academic institutions to conduct international studies designed to support regulatory filings with agencies in North America, Europe and other regions. Verona Pharma’s global reach enables it to engage a broad spectrum of respiratory specialists and patient communities. Under the leadership of Chief Executive Officer Mark Sumeray, Verona Pharma’s management team brings extensive experience in biopharmaceutical development, commercialization and strategic partnerships. The board and executive group guide the company’s efforts to advance its pipeline, secure regulatory milestones and explore business development opportunities aimed at delivering novel treatments for patients with unmet needs in respiratory care.View Verona Pharma PLC American Depositary Share ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Citigroup (10/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
